Hello:
I had been following a thread originally started by Renee543 titled "Starting Sofosbuvir GS-5885". A lot of posts covering numerous related topics of discussion started piling onto that thread, so I thought I would start a new thread here, with the intent of letting folks post their treatment status if desired, so others in the same leaky boat might be able to get a feel for how they were doing with regard to all of us as a class. For example, I did not achieve RVR4 and was a little freaked out about that, but then a few others posted that they, too, did not achieve RVR4, but did, like me, achieve EVR6. So those were somewhat reassuring data points for me, knowing that there were others out there with similar treatment responses.
I am genotype 1b, baselined at 3.1M IU/ml, failed back-to-back non-pegylated interferon monotherapy twice, failed non-pegylated interferon plus ribavirin duotherapy once, and failed pegylated interferon plus ribavirin plus boceprevir triple-therapy once. I was biopsied at stage 3 grade 4 about 2.5 years ago.
I was admitted into the ION-2 trial and assigned to group 3, 12-week sofosbuvir plus ledipasvir without ribavirin. Side effects wer extremely minimal. As I had remarked to my hepatologist, in my case, if I didn't know that ION-2 was an open-lablel study, I would have sworn that I was assigned to the placebo group. I did, perhaps, get a slight recurrence of vertigo, for which I had prior history, and which has now subsided post-treatment, and I decided that I need new glasses but that is likely more related to old age than to sofosbuvir or ledispasvir. I did develop some colitis-like symptoms, but in retrospect, they may have been extrahepatic symptoms first beginning to develop way prior to enrollment in ION-2. I still have those, sometimes I think they are improving, sometimes not so much.
At week 1 in ION-2, I had a 4.3 log reduction in viral load count, down to 143. At weeks 2 and 4, I was less than 25 but detectable. Commencing at week 6 until end of treatment at week 12, I was undetectable. It is my understanding that the particular assay used by the lab can quantify viral load at greater than or equal to 25 IU/ml and can detect but not quantify to as low as 7.1 IU/ml. So, I was somewhere between 0 and 7.1, inclusive, at end of treatment, week 12.
One and a half weeks ago, I had my EOT+4 blood draw. As all of us in ION-2 know, the Sponsor does not share viral load data with the research clinic or us participants. But they do share the "safety panels" (ALT, AST, glucose, albumin, etc., etc.), at least they share the EOT+4wk safety panel data. Mine raised a couple of flags, but I think they are just yellow flags, not red flags, for now, anyways. My glucose, which had been pretty high prior to my attaining undetectable but fell within normal reference range limits once I had achieved undetectable at weeks 6 through 12, has re-elevated to about triple the upper limit again. AST, although still within the normal reference range, has elevated to its highest level since treatment week 6.
Latille had posted a comment in Renee543's thread that the way the informed consent document read, implied that, if applicable, the Sponsor would not request blood samples to confirm relapse until shortly after submission of EOT+12wk sample, but If the participant were undetectable at EOT+12, (s)he would be invited to schedule an appointment for EOT+24 blood sample collection. After I reviewed the informed consent document, the way it was worded, I would concur with that interpretation. My research coordinator person disagreed with that opinion, but then again, I don't think any other participants at my location have been asked to provide a confirmation sample so I don't think my research coordinator could definitively dispute that interpretation by way of example. So, not having been asked yet to provide a blood sample for confirmation testing doesn't really shed any light on the situation. Only the converse situation would. So I may explore independently obtaining a viral load test such as National Genetics Institute's "QuantaSure" test, which boasts of being able to detect viremia as low as 2 IU/ml. I understand that it ain't cheap to do test that, though.
Anyways, that's where I am at today. I invite others to post how their profile (e.g., genotype, baseline VLC, etc.) treatment status (i.e., treatment regimen -- which cohort group, your VLC data by week, clinically significant blood chem data, how far along in your treatment regimen you are), and more importantly, your post treatment status, has gone/is going, so all us ION-2 folks can, as a class, gauge how we all are coming along battling HCV. As a minimum, other participants can at least gauge their own personal progress, to some extent, in comparison to me.
So best wishes to us all,
still_above_dirt